Publication | Closed Access

Second and third line hormonotherapy in advanced post-menopausal breast cancer: a multicenter randomized trial comparing medroxyprogesterone acetate with aminoglutethimide in patients who have become resistant to tamoxifen

Medroxyprogesterone AcetateBreast OncologyMedicineThird Line HormonotherapyPharmacologyGynecologyMenopausal Hormone TherapyBreast CancerMenopausePharmacotherapyOncologyGynecology OncologyEndocrine-related CancerWomen's HealthMenopause Hormone Therapy